Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: 55 | History Defined

Fourth Covid booster vaccine 'significantly' improves protection over just three jabs

It is "over and above" the level of protection that people who have had their third jab receive, according to the latest research.

Daily Record

Covid vaccines safe for pregnant women and cut stillbirth risk, says review

Chance of stillbirth reduced by 15%, researchers find, after examining studies and trials that enrolled 117,552 women

The Guardian - UK

Fourth booster ‘significantly’ increases Covid protection

Levels of antibodies waned in period between third jabs and fourth boosters

Wales Online

From analysis to the latest developments in health,
read the most diverse news in one place.

Covid: ‘Vaccine ceiling’ approaching for some as study suggests fourth jab may not be necessary

A ‘hint’ that some people might have already reached ‘ceiling’ in terms of protection they could acquire from fourth jab

The Independent UK

Fourth Covid jab can give higher immunity than initial booster, study finds

UK-based team finds antibodies peaked higher after fourth jab given after gap of more than six months than after third

The Guardian - UK

Fourth booster ‘significantly’ increases protection

Academics have been monitoring the levels of protection post-vaccination.

The Independent UK

Phuket boy's blindness due to sinusitis, not Pfizer jab

A 12-year-old boy in Phuket did not lose his sight because of Pfizer's coronavirus vaccine but due to severe complications from sinusitis, medical experts on the island province said.

Bangkok Post

Read news from The Economist, FT, and more,
with one subscription

High-risk COVID-19 patients can now get two antiviral prescription drugs — but some are still missing out

For Australians at high risk of developing severe COVID-19, getting access to potentially lifesaving treatments recently became easier — but experts say some people are still having trouble obtaining them.

ABC News

Rare cases of COVID returning pose questions for Pfizer pill

A small number of COVID-19 patients are relapsing after taking Pfizer's antiviral pill, raising questions about the drug at the center of the U.S. response effort

The Independent UK

Pfizer's Ex-Dividend Date Is Thursday, Here's What You Need To Know

Wednesday marks the last chance for investors to receive the next dividend payout from Pfizer (NYSE:PFE).

Benzinga

Affordable Covid drugs kept out of reach by sluggish WTO

Analysis: EU and US pharma giants’ intellectual property rights stop poorer countries accessing vital medication – despite WTO claims of progress

The Guardian - UK

Thailand's first lot of local Covid vaccine produced

The first batch of ChulaCov19, the first messenger-RNA vaccine developed in Thailand, has been produced and is awaiting Food and Drug Administration (FDA) approval for the first two phases of human trials, a government spokesperson said on Saturday.

Bangkok Post

Researchers Want Pfizer's Therapy Studied As Evidence Suggests Benefit for Long COVID Patients: Reuters

Additional reports of patients with long COVID who were helped by Pfizer Inc's (NYSE: PFE) oral antiviral treatment Paxlovid have surfaced, providing momentum for conducting clinical trials to test the treatment,

Benzinga

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

U.S. FDA extends review of Pfizer and Myovant Sciences supplemental New Drug Application (sNDA) For MYFEMBREE by three months

The U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) from Pfizer Inc.

The Independent UK

Mother, 36, most likely died from Covid Pfizer vaccine 11 days after dose, inquest told

Pathologist said the mother-of-two may still be alive had she not had the Covid vaccine

Asharq Al-Awsat

US Drug Regulator Limits Use of J&J Covid Vaccine

The US said Thursday only adults who "have personal concerns" about mRNA vaccines, access issues or medical reasons for refusing them may now receive the Johnson & Johnson Covid shot, which has been linked to a rare but serious clotting condition. The vaccine, which was authorized as a single shot,…

McClatchy Washington Bureau

FDA limits use of Johnson & Johnson COVID vaccine over blood clot risks, agency says

The use of Johnson and Johnson’s COVID-19 vaccine, also known as Janssen, has been limited to “certain individuals” over rare blood clot risks, the U.S. Food and Drug Administration announced Thursday, May 5.

Get all your
news in one place.

100's of premium titles.
One news app.

Daily Mirror

Mum-of-two, 36, died from rare complications of Covid jab, inquest reveals

Mrs Wooldridge was found dead in her home by her brother in June last year, after she failed to collect her five-year-old son from school

The Independent UK

FDA restricts J&J's COVID-19 vaccine due to blood clot risk

U.S. regulators are strictly limiting who can receive Johnson & Johnson’s COVID-19 vaccine due to a rare but serious risk of blood clots

Benzinga

FDA Berates Pfizer CEO's Suggestion To Take More Paxlovid If COVID-19 Symptoms Rebound

The FDA berates Pfizer Inc (NYSE: PFE) CEO Albert Bourla's proposed solution in cases where virus levels rebound after the first course of treatment.

Los Angeles Times

Commentary: COVID won’t become endemic until we have a vaccine for kids under 5

Last week, Moderna became the first manufacturer to officially ask the Food and Drug Administration to approve its COVID-19 vaccine for children under 6 years old. One of three companies with authorized COVID-19 vaccines in the United States, Moderna made the request a month after saying its data showed efficacy…

Axios

COVID-19 dashboard: Catch up fast

The latest headlines that you need to know.

Tribune News Service

FDA contradicts Pfizer’s advice on 2nd course of COVID drug

There is “no evidence” that a second course of Pfizer Inc.’s Paxlovid will help COVID-19 patients whose symptoms return after an initial course of the antiviral, a U.S. Food and Drug Administration official said a day after Pfizer executives advocated the idea.

The Hindu

Pfizer opens global drug development centre on IIT-M Research Park campus

This is the company’s first such facility in Asia

1 … 54 55 56 57

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

349 stories

PFE

346 stories

Centers for Disease Control and Prevention

318 stories

Pfizer Inc

313 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.